Big pharma, Biotech, Partnering, Pharma

X-chem and Pfizer sign a pharma deal for orphan diseases

Posted on 12 June 2014

Tags: , ,

X-Chem announced a multi-target pharma deal with Pfizer.

The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel leads for the Pfizer programs.

Pfizer has an exclusive option to license any compounds generated in the course of the collaboration.

The financial terms of the agreement were not disclosed.

For further deal information visit Current Agreements (subscription required)


Report: Partnering Deals and Alliances with Pfizer

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply